OEHHA Proposes to List Cancer Drug Under the Formally Required to be Labeled and Identified Mechanism of Proposition 65


The California Environmental Protection Agency’s Office of Environmental Health Hazard Assessment (OEHHA) announced that it intends to list bevacizumab as known to the state to cause reproductive toxicity (developmental and female endpoints) under the Safe Drinking Water and Toxic Enforcement Act of 1986, more commonly known as Proposition 65.  OEHHA notes that this action is being proposed under the “Formally Required to Be Labeled or Identified” listing mechanism. which is most often used to list certain drugs approved by the U.S Food and Drug Administration that cover or contain chemical compounds under Proposition 65.  Listings under the Formally Required to be labeled or Identified listing mechanism are rarely contested in any meaningful way.


For example, the proposed listing of Bevacizumab is a cancer treatment drug known by its brand name, Avastin. It is a treatment for many different types of cancers, such as colon cancer, non-small lung cancer and also in the treatment of ovarian cancer.  It is also used in chemotherapy.



Toxicological Endpoint




Female reproductive toxicity

Developmental toxicity

FDA (2018)

About Jack Schatz

Jack Schatz began writing about Proposition 65 and other U.S. environmental laws in 1994. He has also written extensively about Consumer Product safety and product liability issues as well. He is the publisher and co-author of the 2013 and 2017 and upcoming 2020 editions of the Proposition 65 Handbook.He was graduated by the San Diego State School of Journalism.
Next Post

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Login to your account below

Fill the forms bellow to register

Retrieve your password

Please enter your username or email address to reset your password.